ANDA 77039, held by Pharmobedient. Citalopram Hydrobromide.
As of Nov 15, 2026, ANDA 77039 (Citalopram Hydrobromide), held by Pharmobedient, was first approved by FDA on Feb 3, 2005, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 3, 2005 | Original application | Approved |
| Citalopram HydrobromideEQ 10MG BASE · tablet;oral | Citalopram Hydrobromide | Discontinued |
| Citalopram HydrobromideEQ 20MG BASE · tablet;oral | Citalopram Hydrobromide | Discontinued |
| Citalopram HydrobromideEQ 40MG BASE · tablet;oral | Citalopram Hydrobromide | Discontinued |
| Nov 15, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 21, 2009 | Supplement 7Labeling | Approved | None posted |
| Oct 29, 2007 | Supplement 5Labeling | Approved | None posted |
| Oct 29, 2007 | Supplement 6Labeling | Approved | None posted |
| Sep 30, 2005 | Supplement 2Labeling | Approved | None posted |
| Apr 29, 2005 | Supplement 1Labeling | Approved | None posted |
| Feb 3, 2005 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
